Relmada Therapeutics Inc [NASDAQ: RLMD] price plunged by -10.00 percent to reach at -$0.04.
The one-year RLMD stock forecast points to a potential upside of 60.92. The average equity rating for RLMD stock is currently 3.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Relmada Therapeutics Inc [RLMD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RLMD shares is $0.87 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RLMD stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Relmada Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 05, 2024. While these analysts kept the previous recommendation, Jefferies dropped their target price from $3.50 to $13. The new note on the price target was released on September 17, 2024, representing the official price target for Relmada Therapeutics Inc stock. Previously, the target price had yet another drop from $3 to $2, while Goldman kept a Sell rating on RLMD stock. On October 14, 2022, analysts decreased their price target for RLMD shares from 90 to 10.
The Average True Range (ATR) for Relmada Therapeutics Inc is set at 0.06 The Price to Book ratio for the last quarter was 0.22, with the Price to Cash per share for the same quarter was set at 1.79.
RLMD Stock Performance Analysis:
Relmada Therapeutics Inc [RLMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.39. With this latest performance, RLMD shares dropped by -22.27% in over the last four-week period, additionally sinking by -89.44% over the last 6 months – not to mention a drop of -93.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RLMD stock in for the last two-week period is set at 30.07, with the RSI for the last a single of trading hit 35.63, and the three-weeks RSI is set at 27.77 for Relmada Therapeutics Inc [RLMD]. The present Moving Average for the last 50 days of trading for this stock 0.7513, while it was recorded at 0.3502 for the last single week of trading, and 2.6569 for the last 200 days.
Insight into Relmada Therapeutics Inc Fundamentals:
Relmada Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.89 and a Current Ratio set at 6.89.
RLMD Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RLMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Relmada Therapeutics Inc go to 25.49%.
Relmada Therapeutics Inc [RLMD] Institutonal Ownership Details
There are presently around $46.06%, or 50.09%% of RLMD stock, in the hands of institutional investors. The top three institutional holders of RLMD stocks are: VANGUARD GROUP INC with ownership of 1.26 million shares, which is approximately 4.1706%. DEEP TRACK CAPITAL, LP, holding 1.23 million shares of the stock with an approximate value of $$3.7 million in RLMD stocks shares; and DEEP TRACK CAPITAL, LP, currently with $$3.6 million in RLMD stock with ownership which is approximately 3.9825%.
